Corporate, financial, product, speech & presentation, press release - You name it!

HalioDx will develop new assays for QIAGEN in the frame of a multi–year and multi–project agreement

HalioDx SAS, an immuno-oncology diagnostic company, today announced the extension of its agreement with QIAGEN to incorporate new developments for cancer diagnostics.


Initially framed to cover a limited number of in-vitro-diagnostic (IVD) development projects conducted by HalioDx on behalf of QIAGEN, both companies have now agreed to extend this R&D service agreement for another four years to include additional cancer IVD development projects.

Partnering activities are conducted at HalioDx by a team of 60 highly qualified collaborators operating in the company facilities in Marseille, France, under the relevant quality system and a Design Control compliant process aligned with US and Europe regulatory requirements.

Stephane Debono, Executive Vice President Operations and Finances of HalioDx commented: “The extension of our partnership with QIAGEN exemplifies our customer-centric vision and the talent and commitment of our teams in delivering on-time complex IVD projects in a highly regulated and competitive context. It is indeed a very positive signal for potential other partners such as pharma companies.”